Neurosarcoidosis following Immune Checkpoint Inhibition.

Loading...
Thumbnail Image

Date

2018-05

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

118
views
27
downloads

Citation Stats

Abstract

Recently, immune checkpoint inhibitors have revolutionized cancer care by enhancing anti-tumor immunity. However, by virtue of stimulating the immune system, they can lead to immune-related adverse events (irAEs). Neurologic irAEs are uncommon but are becoming increasingly recognized and can be quite serious or even fatal. Furthermore, central nervous system (CNS) manifestations may be difficult to distinguish from CNS metastases, posing management challenges. Here, we describe a patient who developed exacerbation of sarcoidosis leading to CNS involvement following dual checkpoint blockade with nivolumab and ipilimumab for metastatic melanoma and review the relevant literature.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1159/000491599

Publication Info

Dunn-Pirio, Anastasie M, Suma Shah and Christopher Eckstein (2018). Neurosarcoidosis following Immune Checkpoint Inhibition. Case reports in oncology, 11(2). pp. 521–526. 10.1159/000491599 Retrieved from https://hdl.handle.net/10161/17398.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Shah

Suma Shah

Associate Professor of Neurology
Eckstein

Christopher Paul Eckstein

Associate Professor of Neurology

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.